The UK DHSC has issued an alert that phenytoin sodium 100mg capsules made by Accord will be out of stock until May.
List view / Grid view
Filter the results
GlaxoSmithKline has announced that it will not be manufacturing or distributing some of its Excedrin products after inconsistencies in ingredient transfer and weight.
The report reveals practical regulatory reforms that could move the globe closer to the UN’s goal of achieving universal health coverage by 2030.
An inspection at a manufacturing facility belonging to Health Pharma has revealed breaches of cGMP regulations, causing the FDA to send a warning letter.
A study suggests the global neoantigen cancer vaccine market will grow exponentially due to expected drug launches, new technology reducing costs and currently unmet needs of the market.
A partnership between Novartis and NHS England includes a proposal to investigate processes that can increase the scale and efficacy of oligonucleotide manufacture.
In a bid to lower the costs of medicines, California's governor has suggested contracting generic drug manufacturers to make pharmaceutical products for the state to sell, according to reports.
Price caps and government regulations will not lower US healthcare costs, instead supply chain and drug pricing reforms are required, says a brief by medical economist.
A study has suggested that while funding for artificial intelligence in pharma was $5.2bn in 2019, overall investment is slowing.
The mAb tislelizumab has been granted approval from Chinese authorities, making Boehringer Ingelheim Biopharmaceuticals the first MAH under the new system.
Henan Kangdi Medical Devices Co Ltd has been sent a warner letter after an inspection found cGMP violations that included failures of the company’s quality unit.
The EMA will collaborate with other medicine regulatory bodies globally in a pilot programme to inspect sterile medicine manufacturers.
Partnering for product characterisation can streamline drug development and create efficiencies in moving from concept to clinic.
The FDA has announced that a notice of proposed rulemaking has been issued that would allow for the importation of certain prescription drugs from Canada which could lead to lower prescription drug prices.
The following excerpt is the introduction from MECO’s whitepaper titled, A Cost Review of WFI Systems. You can download the full version of this whitepaper at MECO’s website.